Enzalutamida y selección de pacientes
|
ENZALUTAMIDA Y SELECCIÓN DE PACIENTES |
1 |
|
Número de diapositiva 2 |
2 |
|
Pca treatment paradigm today |
3 |
|
The dilemma of choosing a systemic treatment for chemotherapy-naïve mCRPC |
4 |
|
Patients´characteristics in mCRPC trials |
5 |
|
Enzalutamide Reduced Risk of Death by 29% |
6 |
|
Enzalutamide at ADT progression reduced the risk of disease progression by 56% versus bicalutamide |
7 |
|
Enzalutamide at ADT progression reduced the risk of radiographic progression versus bicalutamide |
8 |
|
Enzalutamide rapidly got patients’ PSA under control compared with bicalutamide |
9 |
|
Comorbidities in CRPC patients |
10 |
|
Safety profile COU-AA-302 vs PREVAIL trial |
11 |
|
Abiraterone vs enzalutamide head-to-head comparison |
12 |
|
Abiraterone vs enzalutamide head-to-head comparison |
13 |
|
Abiraterone vs enzalutamide head-to-head comparison |
14 |
|
Abiraterone vs enzalutamide head-to-head comparison |
15 |
|
Abiraterone vs enzalutamide head-to-head comparison |
16 |
|
Número de diapositiva 17 |
17 |
|
Kaplan-Meier Plots of Time to (A) PSA Progression, (B) rPFS, and (C) OS, by Level of Greatest Confirmed PSA Decline From Baseline Within First 3 Months of Treatment In Enzalutamide Arm of PREVAIL |
18 |
|
Best Radiographic Response by Level of Greatest Confirmed PSA Decline From Baseline Within First 3 Months of Treatment on Enzalutamide Arm of PREVAIL (ITT Patients With Measurable Disease) |
19 |
|
Guidelines vs ‘real world’ |
20 |
|
Age and clinical outcome with enzalutamide |
21 |
|
Age and clinical outcome with enzalutamide |
22 |
|
Age and clinical outcome with enzalutamide |
23 |
|
Guidelines vs ‘real world’ |
24 |
|
Guidelines vs ‘real world’ |
25 |
|
Seizures and enzalutamide: Myth or reality? |
26 |
|
Seizures and enzalutamide: Myth or reality? |
27 |
|
Cardiovascular toxicities of systemic treatments of prostate cancer |
28 |
|
Número de diapositiva 29 |
29 |
|
Overview of PK and DDIs in patients treated with abiraterone and enzalutamide |
30 |
|
Actual and predicted DDIs between abiraterone-prednisone and enzalutamide |
31 |
|
Actual and predicted DDIs between abiraterone-prednisone and enzalutamide |
32 |
|
Actual and predicted DDIs between abiraterone-prednisone and enzalutamide |
33 |
|
Against normal perception |
34 |
|
Conclusions |
35 |
|
Número de diapositiva 36 |
36 |